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Moreover, women fare worse than their male counterparts at the time of and after an acute cardiac event. Women presenting with ST-segment elevation myocardial infarction are generally 6-7 years older than men, have more comorbidities and are half as likely as men to receive optimal evidence-based interventions for acute cardiac events. 2 In addition, women have reduced access to preventive treatment and guidance for the long-term management of cardiovascular risk factors. 1 Partly as a result of these differences, women with a history of CHD represent a very high-risk group for future events, with their risk of serious adverse events, including death, more than double that of men. 2 Compounding the issue for women is that the pathophysiology for their developing CHD often differs from the archetypal obstructive flow-limiting atherosclerotic disease seen in men. Indeed, women's acute cardiac events are often ischaemic, but not related to obstructed coronary flow, making 'coronary heart disease' a misnomer. 3 It is increasingly recognised that women frequently experience an expanded spectrum of cardiac diseases that include microvascular and endothelial dysfunction, 1 which are associated with diminished event-free survival. 3 The reasons for the dire outcomes include the delay in recognition and treatment of these ischaemic cardiac events. 1 For example, in the acute setting women often present with more atypical symptoms such as weakness, fatigue and nausea, or pain in the neck, jaw and back, which are not characteristically experienced by men. 1 Long-term and aggressive management of women's cardiovascular risk factors through secondary prevention strategies is needed to curtail the risk of CHD progression and further cardiovascular events.
Initially developed in the 1950s, cardiac rehabilitation (CR) has evolved into a formalised secondary prevention programme recommended following an acute cardiac event. The early programmes primarily focused on exercise therapy to assist men returning to paid work and physical activities. 4 Over the decades since then, CR has become a multidisciplinary approach to improve not only a patient's physical status but also their psychological recovery, and to address lifestyle modifications to aid rehabilitation and reduce secondary cardiac events. 4 The beneficial effects of CR include reductions in hospital readmissions, both in the short and long term, resulting in economic benefits through reductions in healthcare costs. 5 Despite the strong evidence in favour of CR, referral by healthcare professionals is poor, particularly for women who are a third less likely than men to be referred to such programmes. 6 This disparity in access to evidence-based care contributes to women's poorer health outcomes in comparison to men's after acute cardiac events. 2 Women's cardiovascular outcomes are further compromised by their poor uptake of CR; even with referral, they are significantly less likely than men to attend and/or complete CR. 6 It is important to understand the disconnect between the confirmed benefits of CR for both women and men, and women's relatively low attendance. Indeed there is some evidence that women experience a greater reduction in mortality (hazard ratio (HR) 0.36, 95% confidence interval (CI) 0.28, 0.45) compared to men (HR 0.51, 95% CI 0.46, 0.56) when they complete CR programmes. 6 It is critical to understand better the secondary prevention needs of women with CHD in order to ensure that CR programmes offered are fit for their purpose. In general, women differ from men in their priorities and preferences for risk factor management, especially secondary prevention. Following an acute cardiac event, women report deficits in the information provided by health professionals, indicating that they would prefer more detailed information regarding angina management and blood pressure control compared with men. 7 In addition, women value more emotional and social support than is usually provided by standard CR programmes, 8 making the programmes initially developed almost 70 years ago due for a genderbased review.
In recent years, there has been increased interest in understanding why the CR programmes that have worked well for men for decades are less acceptable to women. A myriad of inter and intra-personal, clinical, provider-level, logistic, service delivery and health system factors help explain barriers for referral to and uptake of CR among patients. 9 Of all these constraints, referral and recommendations by medical staff including general physicians and cardiologists are the most consistently identified factors predicting patient CR enrolment and completion. 10 Urgent action is needed to ensure that these healthcare professionals are cognisant of the benefits of CR for women with cardiac disease.
Nonetheless, CR also needs to adapt to women's preferences. Developing collaborative patient-centred approaches to CR by offering a variety of models tailored to suit individual needs is pivotal to improving women's participation and adherence to secondary prevention in the long term. Alternative models of CR such as web-based platforms have the potential to overcome many of the logistic barriers proffered as reasons for non-attendance by women. 11 Other strategies that may be more favourable among women are community-based nurse-led, multidisciplinary programmes similar to MyAction. 12 These programmes potentially have more capacity to address both secondary prevention in women with established CVD as well as primary prevention among those with major risk factors for developing CHD.
Whatever the shape of programmes in the future, it is crucial that concerted efforts are made to improve women's referral to and uptake of CR if their cardiovascular health outcomes are to be improved. However, if the full benefits of CR are to be realised, greater efforts are also needed to ensure that programmes address the needs of women, both in their form and content. In addition, research investigating programmes to address women's preponderance for non-traditional cardiovascular risk factors and non-occlusive cardiac diseases are also lacking. 1 As such, a gap exists regarding the health benefits of both traditional and alternative models of CR programmes for women. Greater efforts are needed to ensure that CR programmes meet the needs of women.
